Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
tom powles
Sep 3, 2024, 14:47 |
Insight
Article of the day, September 3rd, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 5, 2024, 01:55 |
Societies
Scientific Committees at the ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…
Jul 14, 2024, 05:55 |
Blog
RNA vaccines generate tumour specific immune responses with limited toxicity
Thomas Powles posted on X: "Personalised cancer vaccine trials have started in the adjuvant setting…
Jul 1, 2024, 14:48 |
Blog
Daniel Castellano: Great proposals in a urothelial cancer workshop at GUARD Symposium 2024
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: “Great discussion and…
Jun 28, 2024, 14:34 |
Blog
María Natalia Gandur Quiroga: Imfinzi Shows Significant Survival Benefits in NIAGARA Phase III Trial
María Natalia Gandur Quiroga shared on LinkedIn: . "Imfinzi Shows Significant Survival Benefits in NIAGARA…
Jun 26, 2024, 15:22 |
Insight
Results from the NIAGARA Phase III trial
AztraZeneca released the results of the NIAGARA phase III trial, where INFINZI (durvalumab) showed EFS…
Apr 28, 2024, 12:38 |
Insight
Piotr Wysocki: Combined treatment (TKI+ICI) does not benefit favorable-risk mRCC patients
Piotr Wysocki recently shared on LinkedIn: "For several years, combined therapy based on the administration of…
Apr 25, 2024, 00:51 |
Insight
New Paper Alert! Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma Authors: T. Powles,…
Mar 15, 2024, 15:26 |
Insight
Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki
Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…
6
7
8
9
10
All:
99
Posts:
91 - 100
Jeff Bridges and Lymphoma: How He Went Against, How He Survived, and More
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 5
Familial Adenomatous Polyposis: Alarming Symptoms, Causes, Types, Diagnosis and Treatment
OncoDaily Party Barcelona
Ben Stiller and Prostate Cancer: How He Went Against, How He Survived, and More
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube